In the last trading session, 1.51 million Allogene Therapeutics Inc (NASDAQ:ALLO) shares changed hands as the company’s beta touched 0.80. With the company’s per share price at $4.26 changed hands at -$0.12 or -2.74% during last session, the market valuation stood at $720.32M. ALLO’s last price was a discount, traded about -61.74% off its 52-week high of $6.89. The share price had its 52-week low at $2.23, which suggests the last value was 47.65% up since then. When we look at Allogene Therapeutics Inc’s average trading volume, we note the 10-day average is 3.62 million shares, with the 3-month average coming to 2.87 million.
Allogene Therapeutics Inc (NASDAQ:ALLO) trade information
Instantly ALLO was in red as seen at the end of in last trading. With action -8.58%, the performance over the past five days has been red. The drop to weekly highs of 4.74 subtracted -2.74% to the stock’s daily price. The company’s shares are showing year-to-date upside of 32.71%, with the 5-day performance at -8.58% in the red. However, in the 30-day time frame, Allogene Therapeutics Inc (NASDAQ:ALLO) is -2.29% down. Looking at the short shares, we see there were 25.01 million shares sold at short interest cover period of 10.45 days.
Allogene Therapeutics Inc (ALLO) estimates and forecasts
Data shows that the Allogene Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 14.52% over the past 6 months, a 13.93% in annual growth rate that is considerably higher than the industry average of 12.20%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2024 revenue estimates. The rating firms predict current quarter revenue for Allogene Therapeutics Inc will rise 41.20%, while the growth in revenue is estimated to hit 26.40% for the next quarter. Year-over-year growth is forecast to reach -57.90% down from the last financial year.
Consensus estimates given by 8 financial analysts project the company’s revenue in the current quarter to hit an average of $10k. 8 analysts are of the opinion that Allogene Therapeutics Inc’s revenue for the quarter ending Jun 2024 will be $10k. The company’s revenue for the corresponding quarters a year ago was $52k and $44k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at -80.80%. The estimates for the next quarter sales put growth at -77.30%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 22.18%. The 2024 estimates are for Allogene Therapeutics Inc earnings to increase by 20.77%, but the outlook for the next 5-year period is at 1.00% per year.
ALLO Dividends
Allogene Therapeutics Inc is expected to release its next quarterly earnings report between May 01 and May 06.
Allogene Therapeutics Inc (NASDAQ:ALLO)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 22.44% of Allogene Therapeutics Inc shares while 73.78% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 95.13%. There are 73.78% institutions holding the Allogene Therapeutics Inc stock share, with FMR, LLC the top institutional holder. As of Dec 30, 2023, the company held 14.93% of the shares, roughly 25.24 million ALLO shares worth $107.53 million.
TPG GP A, LLC holds the second largest percentage of outstanding shares, with 11.07% or 18.72 million shares worth $79.73 million as of Dec 30, 2023.
Among Mutual Funds, the top two as of Jan 30, 2024 were Fidelity Select Portfolios – Health Care and Vanguard Total Stock Market Index Fund. With 4.0 million shares estimated at $17.04 million under it, the former controlled 2.37% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 2.29% of the shares, roughly 3.88 million shares worth around $16.51 million.
